Seminari di Ematologia Oncologica - Società Italiana di Ematologia

44 Seminari di Ematologia Oncologica
Results of a prospective randomized study of the
German Low Grade Lymphoma Study Group (GLSG).
Blood. 2006; 108: 4003-8.
70. Smith MR, Zhang L, Gordon LI, Foran J, Kahl B,
Gascoyne RD, et al. Horning phase II study of R-
CHOP followed by 90Y-Ibritumomab Tiuxetan in
untreated mantle cell lymphoma: eastern cooperative
oncology group study E1499 (Abstract). Blood.
2007; 110: 389.
71. Dreyling M, Weigert O, Hiddemann W; European MCL
Network. Current treatment standards and future
strategies in mantle cell lymphoma. Ann Oncol.
2008;19: iv41-4.
72. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes
A, et al. Nonablative allogeneic stem-cell transplantation
for advanced/recurrent mantle-cell lymphoma.
J Clin Oncol. 2003; 21: 4407-12.
73. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi
A, Hosing C, et al. Mature results of the M. D.
Anderson Cancer Center risk-adapted transplantation
strategy in mantle cell lymphoma. Blood. 2009; 113:
4144-52.
74. Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker
R, Kofahl-Krause D, et al. Bendamustine plus rituximab
is effective and has a favorable toxicity profile in the treatment
of mantle cell and low-grade non-Hodgkin’s lymphoma.
J Clin Oncol. 2005; 23: 3383-9.
75. Rodríguez J, Gutierrez A, Palacios A, Navarrete M,
Blancas I, Alarcón J, et al. Rituximab, gemcitabine and
oxaliplatin: an effective regimen in patients with refractory
and relapsing mantle cell lymphoma. Leuk
Lymphoma. 2007; 48: 2172-8.
76. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA,
Samaniego F, et al. Phase II study of yttrium-90-ibritumomab
tiuxetan in patients with relapsed or refractory
mantle cell lymphoma. J Clin Oncol. 2009; 27:
5213-8.
77. Pérez-Galán P, Dreyling M, Wiestner A. Mantle cell
lymphoma: biology, pathogenesis, and the molecular
basis of treatment in the genomic era. Blood. 2011;
117: 26-38.
78. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B,
Robertson MJ, de Vos S, et al. Multicenter phase II
study of bortezomib in patients with relapsed or
refractory mantle cell lymphoma. J Clin Oncol. 2006;
24: 4867-74.
79. Martínez N, Camacho FI, Algara P, Rodríguez A,
Dopazo A, Ruíz-Ballesteros E, et al. The molecular
signature of mantle cell lymphoma reveals multiple
signals favoring cell survival. Cancer Res. 2003; 63:
8226-32.
80. Weigert O, Pastore A, Rieken M, Lang N, Hiddemann
W, Dreyling M. Sequence-dependent synergy of the
proteasome inhibitor bortezomib and cytarabine in
mantle cell lymphoma. Leukemia. 2007; 21: 524-8.
81. Weigert O, Unterhalt M, Hiddemann W, Dreyling M.
Mantle cell lymphoma: state-of-the-art management
and future perspective. Leuk Lymphoma. 2009; 50:
1937-50.
82. Ruan J, Martin P, Furman RR, Lee SM, Cheung K,
Vose JM, et al. Bortezomib Plus CHOP-Rituximab for
Previously Untreated Diffuse Large B-Cell Lymphoma
and Mantle Cell Lymphoma. J Clin Oncol. 2010 Dec
28. (Epub ahead of print).
83. Kaufmann H, Raderer M, Wöhrer S, Püspök A, Bankier
A, Zielinski C, et al. Antitumor activity of rituximab plus
thalidomide in patients with relapsed/refractory mantle
cell lymphoma. Blood. 2004; 104: 2269-71.
84. Habermann TM, Lossos IS, Justice G, Vose JM,
Wiernik PH, McBride K, et al. Lenalidomide oral
monotherapy produces a high response rate in
patients with relapsed or refractory mantle cell lymphoma.
Br J Haematol. 2009; 145: 344-9.
85. Zinzani PL, Witzig TE, Vose JM, Reeder CB, Buckstein
R, Haioun C, et al. Confirmation of the efficacy and
safety of Lenalidomide oral monotherapy in patients
with relapsed or refractory mantle-cell lymphoma:
results of an International study (NHL-003) [Abstract].
Blood. Nov 2008; 112: 262.
86. Witzig TE, Geyer SM, Ghobrial I, Inwards DJ,
Fonseca R, Kurtin P, et al. Phase II trial of single-agent
temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
J Clin Oncol. 2005; 23: 5347-56.
87. Hess G, Herbrecht R, Romaguera J, Verhoef G,
Crump M, Gisselbrecht C, et al. Phase III study to
evaluate temsirolimus compared with investigator’s
choice therapy for the treatment of relapsed or refractory
mantle cell lymphoma. J Clin Oncol. 2009; 27:
3822-9.
88. Witzig TE, Reeder CB, Laplant BR, Gupta M,
Johnston PB, Micallef IN, et al. A phase II trial of the
oral mTOR inhibitor everolimus in relapsed aggressive
lymphoma. Leukemia. 2011; 25: 341-7.
89. Renner C, Zinzani PL, Gressin R, Klingbiel D, Favet
L, Hitz F, et al. A multi-center phase II study (SAKK
36/06) of single agent everolimus (RAD001) in
patients with relapsed or refractory mantle cell lymphoma
(Abstract). Blood. 2010; 116: 2803.
90. Lin TS, Blum KA, Fischer DB, Mitchell SM, Ruppert
AS, Porcu P, et al. Flavopiridol, fludarabine, and rituximab
in mantle cell lymphoma and indolent B-cell
lymphoproliferative disorders. J Clin Oncol. 2010; 28:
418-23.
91. Lannutti BJ, Meadows SA, Herman SE, Kashishian A,
Steiner B, Johnson AJ, et al. CAL-101, a p110{delta}
selective phosphatidylinositol-3-kinase inhibitor for the
treatment of B-cell malignancies, inhibits PI3K signaling
and cellular viability. Blood. 2011; 117: 591-4.
92. Brown J, Byrd J, Furman R, Flinn I, Benson D, Coutre
D, et al. Clinical activity in a phase I study of CAL-101,
an isoform-selective inhibitor of phosphatidylinositol 3-
Kinase P110 delta, in patients with B-Cell malignancies
(Abstract). Haematologica. 2010; 95 (Suppl. 2): 466.
93. Morschhauser F, Seymour JF, Kluin-Nelemans HC,